Ocular Therapeutix Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.64
- Today's High:
- $3.89
- Open Price:
- $3.83
- 52W Low:
- $2.57
- 52W High:
- $7.96
- Prev. Close:
- $3.88
- Volume:
- 454016
Company Statistics
- Market Cap.:
- $308.01 million
- Book Value:
- 0.039
- Revenue TTM:
- $54.60 million
- Operating Margin TTM:
- -153.89%
- Gross Profit TTM:
- $-6508000
- Profit Margin:
- -166.17%
- Return on Assets TTM:
- -35.53%
- Return on Equity TTM:
- -263.41%
Company Profile
Ocular Therapeutix Inc had its IPO on 2014-07-25 under the ticker symbol OCUL.
The company operates in the Healthcare sector and Biotechnology industry. Ocular Therapeutix Inc has a staff strength of 274 employees.
Stock update
Shares of Ocular Therapeutix Inc opened at $3.83 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.64 - $3.89, and closed at $3.66.
This is a -5.67% slip from the previous day's closing price.
A total volume of 454,016 shares were traded at the close of the day’s session.
In the last one week, shares of Ocular Therapeutix Inc have slipped by -5.43%.
Ocular Therapeutix Inc's Key Ratios
Ocular Therapeutix Inc has a market cap of $308.01 million, indicating a price to book ratio of 4.8976 and a price to sales ratio of 4.1736.
In the last 12-months Ocular Therapeutix Inc’s revenue was $54.60 million with a gross profit of $-6508000 and an EBITDA of $-81890000. The EBITDA ratio measures Ocular Therapeutix Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Ocular Therapeutix Inc’s operating margin was -153.89% while its return on assets stood at -35.53% with a return of equity of -263.41%.
In Q2, Ocular Therapeutix Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 23.8%.
Ocular Therapeutix Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.19 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ocular Therapeutix Inc’s profitability.
Ocular Therapeutix Inc stock is trading at a EV to sales ratio of 3.3213 and a EV to EBITDA ratio of -3.2833. Its price to sales ratio in the trailing 12-months stood at 4.1736.
Ocular Therapeutix Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $122.56 million
- Total Liabilities
- $32.36 million
- Operating Cash Flow
- $-1990000.00
- Capital Expenditure
- $1.99 million
- Dividend Payout Ratio
- 0%
Ocular Therapeutix Inc ended 2023 with $122.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $122.56 million while shareholder equity stood at $3.09 million.
Ocular Therapeutix Inc ended 2023 with $11.78 million in deferred long-term liabilities, $32.36 million in other current liabilities, 8000.00 in common stock, $-667842000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $66.61 million and cash and short-term investments were $66.61 million. The company’s total short-term debt was $3,796,000 while long-term debt stood at $53.28 million.
Ocular Therapeutix Inc’s total current assets stands at $100.71 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $27.31 million compared to accounts payable of $3.57 million and inventory worth $2.20 million.
In 2023, Ocular Therapeutix Inc's operating cash flow was $-1990000.00 while its capital expenditure stood at $1.99 million.
Comparatively, Ocular Therapeutix Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $3.66
- 52-Week High
- $7.96
- 52-Week Low
- $2.57
- Analyst Target Price
- $13.13
Ocular Therapeutix Inc stock is currently trading at $3.66 per share. It touched a 52-week high of $7.96 and a 52-week low of $7.96. Analysts tracking the stock have a 12-month average target price of $13.13.
Its 50-day moving average was $4.29 and 200-day moving average was $4.76 The short ratio stood at 5.72 indicating a short percent outstanding of 0%.
Around 518.5% of the company’s stock are held by insiders while 5213.3% are held by institutions.
Frequently Asked Questions About Ocular Therapeutix Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. Ocular Therapeutix, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). The company was incorporated in 2006 and is headquartered in Bedford, Massachusetts.